U.S. firms operating in Asia are adapting to global trade uncertainty with a range of survival tactics, from reviewing how goods are classified to tweaking their supply chains.

Few jobs in a global business are as tough as compliance and procurement. So it’s no surprise that those individuals have some concerns.

China won’t find it easy to make good on its promise to crack down on fentanyl as part of its trade war truce with U.S. President Donald Trump.

Increasing wariness in Washington over China’s investments in U.S. biotechnology companies may cool a hot source of capital for medical startups.